AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05022927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial
Study NCT05022927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial
Study NCT04998032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: supaglutide injection+metformin
Description: supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
Study NCT04998032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo+metformin
Description: placebo subcutaneous injection combined with metformin treatment
Study NCT05889221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug and medical device
Description: Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
Study NCT06543407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWITCH IT
Description: Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6.
Study NCT06543407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cig Provision Only
Description: Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
Study NCT05288504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-002
Description: Dose of 600 mg administered subcutaneously three times during the study.
Study NCT05288504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sourced as normal saline administered subcutaneously three times during the study.
Study NCT05605899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered intravenously
Study NCT05605899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally
Study NCT05879991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 (C-14) formulation 1
Description: BI 1810631 (C-14) formulation 1
Study NCT05879991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631
Study NCT05879991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 (C-14) formulation 2
Description: BI 1810631 (C-14) formulation 2
Study NCT05813132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM Protocol
Description: BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
Study NCT05813132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEM protocol
Description: CEM (Carboplatin, Etoposide, Melphalan)
Study NCT06084260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
Study NCT06084260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-compassion group
Description: Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
Study NCT06269900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
Study NCT06269900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
Study NCT05835037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate 30 MG
Description: Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
Study NCT05835037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one placebo tablet per day for 1 year
Study NCT05110859 — intervention group
Intervention type: OTHER
Intervention: in-depth individual interviews
Description: in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
Study NCT05638867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel + Rivaroxaban
Description: Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
Study NCT05638867 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin + Clopidogrel
Description: Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
Study NCT04732962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposHealth
Description: AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately.
Study NCT04732962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Description: A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
Study NCT04732962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement (TKR)
Description: A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
Study NCT04547595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: given by Expert in this method
Study NCT06054776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsies
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06054776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06054776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT06054776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05258825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoferric
Description: A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
Study NCT05686057 — intervention group
Intervention type: DEVICE
Intervention: percutanous coronary angiography with stenting
Description: Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
Study NCT05105295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive a third dose of inactivated COVID-19 vaccine
Study NCT05576792 — intervention group
Intervention type: OTHER
Intervention: Ranibizumab
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
Study NCT06167187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral inferior alveolar nerve block
Description: Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
Study NCT06167187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac and fentanyl
Description: in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
Study NCT06468345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Application was made to CV12, ST25, SP6, HT7 and LI4 acupressure areas.
Study NCT06468345 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Area different from acupressure area
Description: Massage application to non-acupressure hand, foot and abdominal areas
Study NCT05314127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% Gel,Top
Description: once daily topical application at night with a cotton tipped applicator on every lesion
Study NCT05314127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
Study NCT05314127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Cream
Description: 5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
Study NCT05314127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: applied once daily at night
Study NCT05094869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Use of mobile health application
Description: The APP would regularly send messages including the medication reminder, health education knowledge, etc.
Study NCT05094869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online interaction
Description: The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
Study NCT05094869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self follow-up reminders
Description: The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
Study NCT05094869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intelligent follow-up reminders
Description: The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
Study NCT05000671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 injection or Placebo(rate=58.3 mg/hr)
Description: To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Study NCT06318364 — intervention group
Intervention type: OTHER
Intervention: NO Intervention
Description: NO Intervention
Study NCT05000671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 injection or Placebo(rate=87.5 mg/hr)
Description: To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Study NCT05042661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture-like transcutaneous electrical nerve stimulation
Description: The intervention group performed Al-TENS therapy 3 times a week for at least 20 minutes each time for 4 consecutive weeks. The second, fourth, and eighth week after the intervention.
Study NCT05244070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986403
Description: Specified dose on specified days
Study NCT05244070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT05244070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT06110923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-846
Description: once administration of Investigational Product
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
Study NCT06110923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D091
Description: once administration of Investigational Product per day
Study NCT04885686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomethasone N RCS
Description: Root canal sealer
Study NCT04885686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endomethasone SP RCS
Description: Root canal sealer
Study NCT06374485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU409 capsules
Description: Oral administration
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofusbuvir + Daclastavir 60 mg
Description: 400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atazanavir
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sofusbuvir + Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
Study NCT04468087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sofusbuvir + Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
Study NCT06046274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous (IV) infusion
Study NCT05723822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system.
Study NCT06046274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab IV infusion
Study NCT05328401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Description: Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
Study NCT05328401 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
Study NCT06535139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief training
Description: Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.
Study NCT06535139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-targeted motivational aids
Description: Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.
Study NCT06535139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare access
Description: Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
Study NCT06112756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant
Description: Oral
Study NCT06112756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT04383496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
Study NCT06646978 — intervention group
Intervention type: DRUG
Intervention: Imatinib (STI571)
Description: Imatinib-based regimen
Study NCT05553353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation--Active
Description: Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
Study NCT05553353 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation--Sham
Description: Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
Study NCT06247761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure at end of hand surgery
Description: skin closure with vicryl rapide suture
Study NCT06585683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation at Day 4
Description: Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB